Discovery Research From The Editor

  1. A Future Renaissance At Catalent? Employees Think So 2/8/2024

    Re Monday's news of the purchase of Catalent by Novo Holdings, the seminal question we needed a more definitive answer to is: What specifically is planned for Catalent as a CDMO? Chief Editor Louis Garguilo got some answers. “Customers have been calling me continuously,” said one Catalent executive he spoke with. 

  2. Beyond (And Better Than) mRNA: T Cell Vaccines 2/1/2024

    During an extraordinary discussion with a historic biotech entrepreneur, he matter-of-factly interjects, “We’re leaving mRNA vaccines in the dust and moving onto a different approach to vaccines.” That ‘dust-generating’ approach is a proprietary T cell-based platform. And it has COVID and many other implications.

  3. Creating T Cell Vaccines In The Sands 1/25/2024

    Like others, Saudi Arabia has been dependent on vaccines supply from abroad. That’s about to change. According to the CEO of Emergex, the Saudis intend to produce a new generation of vaccines – predominantly based on "T cell priming, the next step beyond mRNA vaccines.”

  4. Vaccine Manufacture From The U.K. to Brazil And Saudi Arabia 1/22/2024

    Why is Professor Thomas Rademacher’s U.K-based vaccine-creating biotech so important that Saudi Arabia has based the establishment of the Kingdom’s first vaccine manufacturing facility on the company? The narrative starts in Brazil.

  5. Reinventing The Classic Pharma Campus 1/15/2024

    Perhaps your company is located on, or considering expanding to, a biopharma or life-sciences campus. Ever wonder how these “campuses” (or “parks”) materialize? Jason Benson of JLL Life Sciences Real Estate Solutions explains to chief editor Louis Garguilo.

  6. Oligonucleotides Outsourcing In 2024 12/26/2023

    2023, among other potential designations, was the year of oligonucleotides. Accordingly, here’s a question I raised with professionals throughout the year: How do you successfully outsource development and manufacture of an oligo program?

  7. Will 2024 Unlock Options Enabling Our Technologies 12/20/2023

    Our Advisory Board members describe their outsourcing experiences during 2023, and offer us ideas and questions on how to make 2004 a better environment, specifically for all our advancing platforms.

  8. How To ID The Best CDMOs 12/13/2023

    It takes a certain, trained perspicuity to identify the CDMO right for you. If you are a small biotech, says CEO Matthias Schroff, you most likely will not have the weight to ensure an external partner’s “real focus on producing for you.” Here's what he recommends.

  9. Considerations And Strategies For Hiring Biopharma Consultants 12/8/2023

    Most organizations do not have the budget or workload to justify a team spanning all possible subspecialties. So, those gaps typically are filled with consultants who add clear value to delivering products and services for the company’s clients. But how do you find the right consultants?

  10. Quality And Regulatory Professionals Joined At The Hip 11/27/2023

    The context and scope of what quality, regulatory, and technical teams – CMC development professionals – need to accomplish has changed dramatically.  It’s a different paradigm, and when you add a CDMO to the mix, it's a very interesting conversation.